Patients who do not need to lose weight typically maintain stable weight on a microdose.
Obesity Reviews , 26 (1), e13839
Although benign in most cases, NAFLD may also evolve to more aggressive phenotypes, including nonalcoholic steatohepatitis (NASH) with or without fibrosis, cirrhosis, liver failure and hepatocellular carcinoma (HCC), which render NAFLD a serious public health concern, if considering the high global prevalence of the disease [3]
Action of glucagon-like peptide-1 (GLP-1) in humans.
GLP-1 agonists were first approved to treat type 2 diabetes in 2005 and have since proven to be extremely effective for weight loss, too
However, inflammation is also necessary (in short bursts) to fight things like infectious invaders